Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Net Income towards Common Stockholders rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Per Silence Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$21.0 million for Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
  • Silence Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $12.3 million during Q4 2024, with a 5-year trough of -$35.5 million in Q3 2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$16.8 million, with a median of -$18.6 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 166.23% in 2024, then plummeted by 1,134.00% in 2025.
  • Over the past 5 years, Silence Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$15.1 million in 2021, then declined by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then spiked by 166.23% to $12.3 million in 2024, then surged by 41.04% to -$21.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.